Optimmune Ophthalmic Ointment None

SECTION 2: Hazards identification

OSHA EMERGENCY OVERVIEW Colorless to light yellow Ointment Odor unknown May cause cancer. May cause effects to: immune system kidney liver

EU Classification

Carc.Cat.2;R45

Potential health effects

The toxicological properties of the mixture(s) have not been fully characterized in humans or animals. However, there are data to describe the toxicological properties of the individual ingredients. The following summary is based upon available information about the individual ingredients of the mixture(s), or of the expected properties of the mixture(s). Cyclosporine is an immunosuppressive agent. Kidney toxicity is a critical side effect with nearly all patients that receive the drug. Long term treatment of cyclosporine can result in chronic kidney damage. Cyclosporine has been classified as a human carcinogen based on studies in humans, which indicate a causal relationship between exposure to cyclosporine and human cancer. Effects in animal studies suggest a low order of acute toxicity. Effects seen in repeat dose studies are consistent with the pharmacological immunosuppressive activity of the drug. Kidney and liver effects have been observed at toxic dose levels. Petrolatum may cause allergic contact dermatitis. Ingestion of petrolatum may cause laxative effects and may result in abdominal cramps and diarrhea. If aspirated, this product may cause lipid pneumonia or lipid granuloma of the lung; however, petrolatum does not present a high risk of aspiration. LISTED CARCINOGENS INGREDIENT CAS NUMBER